Gefitinib therapy for non-small cell lung cancer
A Birnbaum, N Ready - Current Treatment Options in Oncology, 2005 - Springer
Opinion statement Gefitinib is a small molecule that specifically inhibits the tyrosine kinase
activity of the epidermal growth factor receptor (EGFR) type 1 by interfering with the …
activity of the epidermal growth factor receptor (EGFR) type 1 by interfering with the …
Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is effective as first‐line treatment of advanced non‐small‐cell lung cancer with mutated EGFR: a …
G Gao, S Ren, A Li, J Xu, Q Xu, C Su… - … journal of cancer, 2012 - Wiley Online Library
Gefiinib and erlotinib are two similar small molecules of selective and reversible epidermal
growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs), which have been approved …
growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs), which have been approved …
[HTML][HTML] Comparison of clinical outcomes following gefitinib and erlotinib treatment in non–small-cell lung cancer patients harboring an epidermal growth factor …
SH Lim, JY Lee, JM Sun, JS Ahn, K Park… - Journal of Thoracic …, 2014 - Elsevier
Background: Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …
Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non–small cell lung cancer: a phase 2 …
TE Stinchcombe, PA Jänne, X Wang, EM Bertino… - JAMA …, 2019 - jamanetwork.com
Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …
Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations
S Morita, I Okamoto, K Kobayashi, K Yamazaki… - Clinical Cancer …, 2009 - AACR
Purpose: Somatic mutations of the epidermal growth factor receptor (EGFR) gene are
associated with an increased response to gefitinib in patients with non–small cell lung …
associated with an increased response to gefitinib in patients with non–small cell lung …
[HTML][HTML] Review of EGFR TKIs in metastatic NSCLC, including ongoing trials
B Melosky - Frontiers in oncology, 2014 - frontiersin.org
Recent clinical trials have demonstrated the efficacy of epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKI) in the treatment of patients with advanced metastatic …
(EGFR) tyrosine kinase inhibitors (TKI) in the treatment of patients with advanced metastatic …
[HTML][HTML] A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama …
H Yoshioka, K Hotta, K Kiura, N Takigawa… - Journal of Thoracic …, 2010 - Elsevier
Backgrounds Efficacy of gefitinib therapy strongly depends on epidermal growth factor
receptor (EGFR)-mutation status in Asian patients with non-small cell lung cancer. Recently …
receptor (EGFR)-mutation status in Asian patients with non-small cell lung cancer. Recently …
Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations
JY Wu, SG Wu, CH Yang, YL Chang, YC Chang… - Lung cancer, 2011 - Elsevier
INTRODUCTION: Erlotinib and gefitinib are tyrosine kinase (TK) inhibitors of epidermal
growth factor receptor (EGFR) that are effective in treating non-small cell lung cancer …
growth factor receptor (EGFR) that are effective in treating non-small cell lung cancer …
Gefitinib alone versus gefitinib plus chemotherapy for non–small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study
Y Hosomi, S Morita, S Sugawara, T Kato… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor combined with
cytotoxic chemotherapy is highly effective for the treatment of advanced non–small-cell lung …
cytotoxic chemotherapy is highly effective for the treatment of advanced non–small-cell lung …
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer
K Kaira, T Naito, T Takahashi, E Ayabe, R Shimoyama… - Lung Cancer, 2010 - Elsevier
PURPOSE: The use of erlotinib after gefitinib failure in patients with non-small cell lung
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …